Anavex Life Sciences Corp (AVXL)

[sokol]

"The RPD designation provides priority review by the FDA to encourage treatments for rare pediatric diseases. Under the RPD program, a sponsor who receives an approval for a drug for a “rare pediatric disease” may qualify for a voucher that can be redeemed to receive a priority review by the FDA of a subsequent marketing application for a different product."

https://www.anavex.com/anavex-life-sciences-receives-rare-pediatric-disease-designation-from-fda-for-anavex2-73-blarcamesine-for-the-treatment-of-rett-syndrome/